ArticleRevista da Associacao Medica Brasileira (1992)2025
Evaluation of 5-methylcytosine and 5-hydroxymethylcytosine levels in juvenile idiopathic arthritis and its types.
Article in Revista da Associacao Medica Brasileira (1992), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Differential transcriptional and epigenetic signatures in CD4Journal of translational autoimmunity · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveJuvenile idiopathic arthritis is the most common chronic rheumatic disease of autoimmune origin in childhood. While altered DNA methylation has been associated with adult autoimmune rheumatic diseases, studies on juvenile idiopathic arthritis remain limited. This study evaluated levels of 5-methylcytosine and 5-hydroxymethylcytosine, important epigenetic biomarkers, in juvenile idiopathic arthritis and its subtypes.
methodsThis single-center cross-sectional study included patients diagnosed with juvenile idiopathic arthritis aged 1 month to 18 years. Children with systemic or autoimmune diseases and comorbidities were excluded. The study comprised 58 juvenile idiopathic arthritis patients and 35 age-gender-matched healthy controls presenting with non-rheumatological complaints. Demographic and clinical characteristics, including juvenile idiopathic arthritis subtypes, were recorded. The 5-methylcytosine and 5-hydroxymethylcytosine levels were assessed quantitatively using an enzyme-linked immunosorbent assay kit. The relationships between 5-methylcytosine and 5-hydroxymethylcytosine and juvenile idiopathic arthritis and its subtypes were evaluated statistically.
resultsThe 5-hydroxymethylcytosine level was significantly higher, whereas the 5-methylcytosine and 5-methylcytosine/5-hydroxymethylcytosine ratios were significantly lower in the patient group than in the control group. No significant differences between different juvenile idiopathic arthritis subtypes and disease activity status were found in 5-hydroxymethylcytosine and 5-methylcytosine levels or 5-methylcytosine/5-hydroxymethylcytosine ratios (p>0.05). The 5-methylcytosine/5-hydroxymethylcytosine ratio, with an optimal cut-off value of ≤28.05, demonstrated a sensitivity of 70.69% and a specificity of 77.14% in distinguishing juvenile idiopathic arthritis patients from controls (p<0.001).
conclusion5-Hydroxymethylcytosine and 5-methylcytosine can be potential biomarkers for juvenile idiopathic arthritis and its subtypes, indicating their roles in juvenile idiopathic arthritis development regarding molecular mechanisms and novel therapeutic approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.